Objective Miltefosine stands as the sole oral medication approved for the treatment of
leishmaniasis. The appearance of severe ophthalmic toxicities induced by miltefosine in the …

Post kala-azar dermal leishmaniasis (PKDL) is a skin disease that usually occurs among
individuals with a past history of visceral leishmaniasis (VL). PKDL cases act as a reservoir …

Para Kala-azar Dermal Leishmaniasis (Para-KDL) manifests the concomitant presence of
Post Kala-azar Dermal Leishmaniasis and Visceral Leishmaniasis and works as a reservoir …

Background Post-kala-azar dermal leishmaniasis (PKDL) is a dermatosis that occurs 2–3
years after an apparently successful treatment of visceral leishmaniasis (VL). In rare cases …

Introduction The ongoing visceral leishmaniasis (VL) elimination programme in India is
targeting the elimination of the disease VL but not the pathogen. The persistence of hidden …

Visceral leishmaniasis (VL) or Kala-azar, primarily caused by Leishmania donovani, is a
major health concern in many countries including India. Growing unresponsiveness among …

Historically, leishmaniasis can be traced back to more than 2500 BC, according to several
hypotheses, fossil records, and molecular results on archaeological resource samples. In …

Visceral leishmaniasis (VL) is a vector–borne disease transmitted by Phlebotomine
sandflies, with up to 350 million people are at risk of developing infection globally. VL has a …

Post-kala-azar dermal leishmaniasis (PKDL) is a complication of visceral leishmaniasis (VL)
that most frequently occurs after an episode of VL caused by Leishmania donovani. In this …